IPO registrations (S-1, F-1) · Registrants

OnKure Therapeutics, Inc.

SEC CIK
1637715 · filings on EDGAR ↗
Former names
Reneo Pharmaceuticals, Inc. (2018–2024)
Registration
Form S-1, first filed 2021-03-19, last 2024-10-23; 2 initial registrations, 1 amendment
Outcome
Final prospectus filed 2021-04-09; declared effective 2021-04-08
Industry (SIC)
Pharmaceutical Preparations 2834
Incorporated in
DE
Business address
6707 WINCHESTER CIRCLE, SUITE 400, Boulder, CO 80301
EIN
47-2309515
Ticker
OKUR (Nasdaq)
EDGAR entity type
operating
Insiders and CEO pay
OnKure Therapeutics, Inc. on the corporate pages

Offering terms

Proposed price range
$15.00–$17.00 per share (S-1/A filed 2021-04-05)
Final price
$15.00 per share, within the range (424B4 filed 2021-04-09, an initial public offering)
Shares sold
6,250,000
Gross proceeds
$93,750,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol RPHM
Lead underwriters
Jefferies; Leerink Partners (2,187,500 shares); Piper Sandler (1,718,750 shares)

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 13

FiledFormWhat it isName as filedEDGAR
2021-03-19S-1S-1 (registration)Reneo Pharmaceuticals, Inc.0001193125-21-087741 ↗
2021-04-05S-1/AS-1/A (amendment)Reneo Pharmaceuticals, Inc.0001193125-21-105697 ↗
2021-04-08EFFECTEFFECT (declared effective)Reneo Pharmaceuticals, Inc.9999999995-21-001364 ↗
2021-04-09424B4424B4 (final prospectus)Reneo Pharmaceuticals, Inc.0001193125-21-111652 ↗
2022-05-09EFFECTEFFECT (declared effective)Reneo Pharmaceuticals, Inc.9999999995-22-001381 ↗
2023-06-13EFFECTEFFECT (declared effective)Reneo Pharmaceuticals, Inc.9999999995-23-001742 ↗
2023-11-21EFFECTEFFECT (declared effective)Reneo Pharmaceuticals, Inc.9999999995-23-003413 ↗
2024-08-26EFFECTEFFECT (declared effective)Reneo Pharmaceuticals, Inc.9999999995-24-002630 ↗
2024-10-23S-1S-1 (registration)OnKure Therapeutics, Inc.0001193125-24-241926 ↗
2024-10-30EFFECTEFFECT (declared effective)OnKure Therapeutics, Inc.9999999995-24-003323 ↗
2025-03-21EFFECTEFFECT (declared effective)OnKure Therapeutics, Inc.9999999995-25-000731 ↗
2025-11-18EFFECTEFFECT (declared effective)OnKure Therapeutics, Inc.9999999995-25-003308 ↗
2026-05-04EFFECTEFFECT (declared effective)OnKure Therapeutics, Inc.9999999995-26-001477 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2021-04-05S-1/Aregistration statement$15.00–$17.006,250,000-Nasdaq RPHM3primary document; range, shares headline, cover names 3document ↗
2021-04-09424B4final prospectus$15.006,250,000$93,750,000Nasdaq RPHM3primary document; price sentence, shares headline, proceeds table, underwriting table 2, cover names 3document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
BASKETT FORESTTenPercentOwner22021
Cardon LonDirector22021
Cruse MichaelOfficerChief Operating Officer; Senior VP, Corporate Operation; Senior VP-Corporate Operations72021–2022
Dorenbaum AlejandroOfficerChief Medical Officer32021–2022
Dube Eric MDirector32021–2023person page Fuzzy
FLESHER GREGORY J.Director,OfficerPresident and CEO42021–2022
Florence Anthony A. Jr.TenPercentOwner22021
GREY MICHAEL GDirector; Director,OfficerExecutive Chairman122021–2026
Harrison Kenneth Ph.D.Director32021
Jindal Vineet R.OfficerChief Financial Officer32021
Johnson Wendy S.OfficerChief Development Officer32021
Kordel JohanDirector12021
Makhzoumi MohamadTenPercentOwner22021
MAKOWER JOSHUATenPercentOwner22021
Mathers Edward TDirector122021–2026
Muralidhar BaliDirector122021–2023
NEA 15 GP, LLCTenPercentOwner22021
NEA Partners 15, L.P.TenPercentOwner22021
New Enterprise Associates 15, L.P.TenPercentOwner22021
Novo Holdings A/STenPercentOwner32021–2023
O'Donnell NiallDirector62021–2023
RiverVest Venture Fund III, L.P.TenPercentOwner22021
RiverVest Venture Fund III (Ohio), L.P.TenPercentOwner22021
RiverVest Venture Fund IV, L.P.TenPercentOwner22021
SANDELL SCOTT DTenPercentOwner22021
Seltzer Stacey DenenbergDirector42021–2023
Sonsini Peter W.TenPercentOwner22021
Hall AshleyOfficerChief Development Officer42021–2023
Hoelscher Paul W.Director42022–2023
Lam JenniferOfficerVP of Finance & Administration22022
Blunt Roshawn A.Director32022–2023
Leonard Braden MichaelOther; TenPercentOwner72024
Agresta SamuelOfficerChief Medical Officer52024–2026
Carruthers R MichaelDirector52024–2026
Hartley DylanOfficerChief Scientific Officer52024–2026
Jansen Valerie MalyvanhDirector52024–2026
Leverone Jason A.OfficerChief Financial Officer122024–2026
Manke IsaacDirector92024–2026
Phillips Andrew JohnDirector52024–2026
Saccomano Nicholas ADirector,OfficerPresident and CEO122024–2026
ACORN BIOVENTURES, L.P.TenPercentOwner22024–2025
ACORN CAPITAL ADVISORS GP, LLCTenPercentOwner22024–2025
Hove Anders DTenPercentOwner22024–2025
Chen BihuaOther; TenPercentOwner32024–2025
Cormorant Asset Management, LPOther; TenPercentOwner32024–2025
Cormorant Global Healthcare Master Fund, LPOther; TenPercentOwner32024–2025
Cormorant Private Healthcare Fund III LPOther; TenPercentOwner32024–2025
Cormorant Private Healthcare Fund IV LPOther; TenPercentOwner32024–2025
Cormorant Private Healthcare Fund V LPOther; TenPercentOwner32024–2025
ACORN BIOVENTURES 2, L.P.TenPercentOwner12025
Acorn Capital Advisors GP 2, LLCTenPercentOwner12025
Ratcliffe LiamDirector42026
Access Industries Holdings LLCTenPercentOwner12026
ACCESS INDUSTRIES MANAGEMENT, LLCTenPercentOwner12026
AI Biotechnology LLCTenPercentOwner12026
Blavatnik LenTenPercentOwner12026

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2024-10-21OnKure Therapeutics, Inc.Pharmaceuticals$65,000,000$65,000,000201
2020-12-21Reneo Pharmaceuticals, Inc.Pharmaceuticals$94,769,998$47,384,999151
2019-05-14Reneo Pharmaceuticals, Inc.Pharmaceuticals$25,000,002$25,000,00291
2018-01-08Reneo Pharmaceuticals, Inc.Pharmaceuticals$51,994,684$21,994,682161

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationOnKure Therapeutics, Inc.State business registriesname and state
Business registrationONKURE THERAPEUTICS, INC.State business registriesname and state
Form 5500 plan sponsorRENEO PHARMACEUTICALS INCEIN (EXACT)
Form D issuerOnKure Therapeutics, Inc.Form D private offeringsCIK (EXACT)
Person pageEric M DubePeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director)
SEC filerOnKure Therapeutics, Inc.SEC filers (EDGAR)CIK (EXACT)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.